|Articles|January 21, 2016

Celltrion Adopts Medidata Clinical Cloud

Medidata's ClinicalCloud will provide scalable technology to Celltrion's biosimilars development programs.

Seoul, Korea-based biopharmaceutical company Celltrion announced it has adopted Medidata's ClinicalCloud to provide scalable technology to its biosimilars development programs. The technologies include electronic data capture and management (Medidata Rave^®), medical coding (Medidata Coder^®) and randomization and trial supply management (Medidata Balance^®).

Read the full release.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe

Related Content

ACT Brief: RBQM Multi-Functional Buy-In and E6(R3), Site Payment Performance and Cash Runway, and Inhaled Therapy for Cystic Fibrosis

ByAndy Studna, Senior Editor

September 9th 2026

Celltrion Adopts Medidata Clinical Cloud

Related Content

ACT Brief: RBQM Multi-Functional Buy-In and E6(R3), Site Payment Performance and Cash Runway, and Inhaled Therapy for Cystic Fibrosis

Why Payment Performance Has Become an Operational Brand for Sponsors: Q&A with Patrick Mizer, Ledger Run

What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale

ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD

Beyond Patient Centricity: What Rare Disease Research Gets Right

Trending on Applied Clinical Trials Online

Beyond Patient Centricity: What Rare Disease Research Gets Right

What This Study Means for Sponsors Still Struggling to Justify RBQM at Scale

ACT Brief: Hidden RBQM Value, Rare Disease Patient Partnership, and Safety Perception in IBD

Why Payment Performance Has Become an Operational Brand for Sponsors: Q&A with Patrick Mizer, Ledger Run

ACT Brief: RBQM Multi-Functional Buy-In and E6(R3), Site Payment Performance and Cash Runway, and Inhaled Therapy for Cystic Fibrosis